Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vistin Pharma ASAOSL:VISTN -4.46%80 Days Payable is 65.75 as of Jun. 2026, which is 12% above its 10-year median of 58.90. GuruFocus rates OSL:VISTN with a GF Score™ of 80/100 and a GF Value™ of kr23.39 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 923 Drug Manufacturers companies, Vistin Pharma ASA ranks worse than 71.72% on this metric.
The historical rank and industry rank for Vistin Pharma ASA's Days Payable or its related term are showing as below:
OSL:VISTN'
s Days Payable Range Over the Past 10 Years
Min: 27.22 Med: 58.9 Max: 162.1
Current: 57.79
During the past 13 years, Vistin Pharma ASA's highest Days Payable was 162.10. The lowest was 27.22. And the median was 58.90.
OSL:VISTN's Days Payable is ranked worse than 71.72% of 923
companies
in the Drug Manufacturers industry
Industry Median: 88.47
vs OSL:VISTN: 57.79
Vistin Pharma ASA's Days Payable
increased
from Jun. 2025 (38.59) to Jun. 2026 (65.75).
It may suggest that Vistin Pharma ASAdelayed paying its suppliers.
The historical data trend for Vistin Pharma ASA's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:VISTN vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Days Payable distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vistin Pharma ASA's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA (OSL:VISTN) has a Days Payable of 65.75 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vistin Pharma ASA and its competitors. This is 12% above median its historical median of 58.90. Over the past decade, Vistin Pharma ASA's Days Payable has ranged from 27.22 to 162.10. According to the industry distribution chart, Vistin Pharma ASA ranks #662 out of 923 companies in the Drug Manufacturers industry, placing it in the top 71.7%.
Is Vistin Pharma ASA's Days Payable too high?
Vistin Pharma ASA's current Days Payable of 65.75 is 12% above median its 10-year median of 58.90. Over the past 10 years, this metric has ranged from a low of 27.22 to a high of 162.10. The Drug Manufacturers industry median Days Payable is 88.47. Vistin Pharma ASA's value of 65.75 is 25.7% below this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #662 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vistin Pharma ASA has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #662 out of 923 companies for Days Payable. This places Vistin Pharma ASA in the lower half of its industry. The industry median Days Payable is 88.47. Vistin Pharma ASA's value of 65.75 is 25.7% below this benchmark. Historically, Vistin Pharma ASA's own Days Payable has ranged from 27.22 to 162.10 over the past decade. While the company's 10-year median is 58.90 vs. the industry median of 88.47, Vistin Pharma ASA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.47, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current Days Payable of 65.75 is 25.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Days Payable is 65.75, which is 12% above median its own 10-year median of 58.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (OSL:VISTN) is currently considered Modestly Undervalued. The stock's GF Value™ is kr23.39, compared to a current price of kr19.30 — trading 17.5% below its estimated fair value. The current Days Payable is 65.75, which is 12% above median its 10-year median of 58.90 and 25.7% below the Drug Manufacturers industry median of 88.47. Vistin Pharma ASA's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vistin Pharma ASA (OSL:VISTN), the current Days Payable is 65.75 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (OSL:VISTN) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr19.30 is trading 17.5% below its estimated GF Value™ of kr23.39.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for OSL:VISTN:
Days Payable: 65.75 (12% above median its 10-year median of 58.90)
GF Value™: kr23.39 vs. price of kr19.30 (17.5% below fair value)
Industry Position: 25.7% below the Drug Manufacturers median (#662 of 923)
No single metric tells the full story. See the OSL:VISTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
80GF Score
Get the complete analysis for OSL:VISTN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:VISTN has been successfully added to your 
